TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03919799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: ROCK-2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: ROCK-2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: ROCK-2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: ROCK-2 Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study: NCT00886899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recanalization of a coronary chronic total occlusion
Description: Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
Study: NCT02820272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NPWT with cold water
Description: Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
Study: NCT00852098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap Nissen fundoplication with division of short gastric vessels
Description: Dividing short gastric vessels
Study: NCT02820272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT with normal saline room temp
Description: Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NPWT without other intervention
Description: Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
Study: NCT03642405

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram examination
Description: 12-lead ECG monitored by Holter
Study: NCT00852098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Nissen fundoplication without division of short gastric vessels
Description: non-dividing short gastric vessels
Study: NCT01876472

Intervention type: BEHAVIORAL
Intervention: Assessment of music perception skills
Description: A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.

Intervention type: BEHAVIORAL
Intervention: Assessment of music perception skills
Description: A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.

Intervention type: BEHAVIORAL
Intervention: Assessment of music perception skills
Description: A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
Study: NCT02682576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial artery ultrasound imaging
Study: NCT00979472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: oral
Study: NCT03100006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg of IV Nivolumab is administered over 30 mins every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
Study: NCT03642405

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram examination
Description: 12-lead ECG monitored by Holter

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram examination
Description: 12-lead ECG monitored by Holter

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography in accordance to Danish Society of Cardiology
Study: NCT02789800

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIMAC02
Description: Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
Study: NCT04696328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human (allogeneic) iPS cell derived-cardiomyocyte sheet
Description: Transplantation
Study: NCT03746340

Intervention type: DRUG
Intervention: Propofol
Description: Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30\~60s. Continuous intravenous infusion of Propofol (7\~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.

Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0\~2.5Vol%) was maintained
Study: NCT02894892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (A)Bismuth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (B)Bismuth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (C)Bismuth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (D)Esomeprazole and Bismuth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (E)Esomeprazole and Bismuth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (F)Esomeprazole and Bismuth

Intervention type: OTHER
Group type: OTHER
Intervention: (G)Control
Study: NCT03180021

Intervention type: PROCEDURE
Intervention: MRI
Description: This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers.

Intervention type: PROCEDURE
Intervention: MRI
Description: This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers.
Study: NCT03151772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: 200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg x 3 taken preoperatively
Study: NCT02918422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Manipulation
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Manipulation
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Manipulation
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Manipulation
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
Study: NCT03642405

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography in accordance to Danish Society of Cardiology

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography in accordance to Danish Society of Cardiology

Intervention type: PROCEDURE
Intervention: Blood Samples
Description: Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).

Intervention type: PROCEDURE
Intervention: Blood Samples
Description: Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).

Intervention type: PROCEDURE
Intervention: Blood Samples
Description: Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding patients quality of life

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding patients quality of life

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding patients quality of life
Study: NCT00718224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study: NCT03669172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor IL-15 stimulated NK cells infusion
Description: DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
Study: NCT03320954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anomia treatment
Description: Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
Study: NCT01773785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1620
Description: SPI-1620 11 μg/m2 will be given intravenously over 1 minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
Study: NCT02480023

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: calcaneal quantitative ultrasound assessment
Description: QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
Study: NCT03972553

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sugarbaker technique for repairing parastomal hernia
Description: The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Keyhole technique for repairing parastomal hernia
Description: The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
Study: NCT04347044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Exercise training+ Optimal medication and clinical follow-up
Study: NCT04419597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOPATCH
Description: The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Usual clinical practice techniques for reinforcing primary dural closure.
Study: NCT03597789

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Helping the Noncompliant Child (HNC)
Description: HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
Study: NCT04114045

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental:Whey protein
Description: Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Isoenergetic control - Carbohydrate
Description: Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
Study: NCT02331654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Description: Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
Study: NCT04347044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart care
Description: Optimal medication and clinical follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standart care
Description: Optimal medication and clinical follow-up
Study: NCT01717560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative, multidisciplinary, integrated care
Description: Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management.
Study: NCT02324036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMPATHy Toolkit
Description: Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
Study: NCT03004027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self help leaflet
Description: Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
Study: NCT02324036

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coached Care
Description: Community health worker provides participation training to patient
Study: NCT04649190

Intervention type: DEVICE
Intervention: TAVI
Description: Coronary access for PCI after TAVI
Study: NCT04103203

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PathoRobot/ Patho-Doc Test result
Description: Test results of the new diagnostics will be available to the treating physician.
Study: NCT03004027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self help leaflet
Description: Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
Study: NCT01423058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles.
Study: NCT02319889

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Undergo SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study: NCT03535116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Toradol is a type of brand name. We will be using the generic version.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: injectable normal saline
Study: NCT02715674

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasti-med TRIFLO

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP VISION

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plasti-med oxygen therapy mask
Study: NCT01990404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed 50% nitrous oxide and oxygen
Description: Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical Air
Description: Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
Study: NCT01482884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tralokinumab
Description: 2 sc injections of every 2 weeks for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 sc injections of every 2 weeks for 12 weeks.
Study: NCT04344925

Intervention type: DEVICE
Intervention: Aerosol-reducing Mask
Description: Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.

Intervention type: DEVICE
Intervention: Standard Mask
Description: Patient will be put on BIPAP using the standard mask
Study: NCT02587715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
Description: Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberation therapy
Study: NCT02762123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142 350mg
Study: NCT06138392

Intervention type: DEVICE
Intervention: Dental implant (ELEMENT RC INICELL, Thommen Medical)
Description: Dental implant